Coloplast A/S (COLO-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coloplast A/S (COLO-B) has a cash flow conversion efficiency ratio of 0.162x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr2.23 Billion ≈ $349.37 Million USD) by net assets (Dkr13.80 Billion ≈ $2.16 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Coloplast A/S - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Coloplast A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read COLO-B liabilities breakdown for a breakdown of total debt and financial obligations.
Coloplast A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coloplast A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Financial Holding Co Ltd
TW:2892
|
-0.010x |
|
Lifco AB (publ)
ST:LIFCO-B
|
0.103x |
|
JBS N.V.
NYSE:JBS
|
0.203x |
|
HMM Co Ltd
KO:011200
|
0.041x |
|
CNH Industrial N.V.
NYSE:CNH
|
0.084x |
|
SOUTH32 Ltd
AU:S32
|
0.060x |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
0.119x |
|
NESTE OYJ UNSP.ADR 1/2
F:NEFA
|
N/A |
Annual Cash Flow Conversion Efficiency for Coloplast A/S (2002–2025)
The table below shows the annual cash flow conversion efficiency of Coloplast A/S from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see COLO-B company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | Dkr16.12 Billion ≈ $2.52 Billion |
Dkr6.64 Billion ≈ $1.04 Billion |
0.412x | +167.36% |
| 2024-09-30 | Dkr17.94 Billion ≈ $2.81 Billion |
Dkr2.77 Billion ≈ $432.76 Million |
0.154x | -36.89% |
| 2023-09-30 | Dkr17.30 Billion ≈ $2.71 Billion |
Dkr4.23 Billion ≈ $661.19 Million |
0.244x | -60.27% |
| 2022-09-30 | Dkr8.29 Billion ≈ $1.30 Billion |
Dkr5.10 Billion ≈ $797.78 Million |
0.615x | -5.05% |
| 2021-09-30 | Dkr8.17 Billion ≈ $1.28 Billion |
Dkr5.29 Billion ≈ $827.66 Million |
0.648x | +0.79% |
| 2020-09-30 | Dkr7.41 Billion ≈ $1.16 Billion |
Dkr4.76 Billion ≈ $744.58 Million |
0.643x | +1.96% |
| 2019-09-30 | Dkr6.91 Billion ≈ $1.08 Billion |
Dkr4.36 Billion ≈ $681.68 Million |
0.630x | -7.25% |
| 2018-09-30 | Dkr6.42 Billion ≈ $1.00 Billion |
Dkr4.36 Billion ≈ $682.31 Million |
0.679x | +24.40% |
| 2017-09-30 | Dkr5.95 Billion ≈ $931.23 Million |
Dkr3.25 Billion ≈ $508.64 Million |
0.546x | -8.58% |
| 2016-09-30 | Dkr5.07 Billion ≈ $792.93 Million |
Dkr3.03 Billion ≈ $473.75 Million |
0.597x | -15.74% |
| 2015-09-30 | Dkr4.71 Billion ≈ $736.29 Million |
Dkr3.34 Billion ≈ $522.10 Million |
0.709x | +41.48% |
| 2014-09-30 | Dkr6.28 Billion ≈ $983.02 Million |
Dkr3.15 Billion ≈ $492.68 Million |
0.501x | +8.18% |
| 2013-09-30 | Dkr6.77 Billion ≈ $1.06 Billion |
Dkr3.14 Billion ≈ $490.65 Million |
0.463x | +5.67% |
| 2012-09-30 | Dkr6.04 Billion ≈ $945.31 Million |
Dkr2.65 Billion ≈ $414.46 Million |
0.438x | -10.96% |
| 2011-09-30 | Dkr4.48 Billion ≈ $700.62 Million |
Dkr2.21 Billion ≈ $344.99 Million |
0.492x | -3.91% |
| 2010-09-30 | Dkr3.45 Billion ≈ $540.09 Million |
Dkr1.77 Billion ≈ $276.77 Million |
0.512x | -20.19% |
| 2009-09-30 | Dkr2.85 Billion ≈ $445.90 Million |
Dkr1.83 Billion ≈ $286.32 Million |
0.642x | +11.11% |
| 2008-09-30 | Dkr2.29 Billion ≈ $358.44 Million |
Dkr1.32 Billion ≈ $207.15 Million |
0.578x | +38.15% |
| 2007-09-30 | Dkr2.40 Billion ≈ $375.50 Million |
Dkr1.00 Billion ≈ $157.08 Million |
0.418x | +21.47% |
| 2006-09-30 | Dkr2.81 Billion ≈ $438.86 Million |
Dkr966.00 Million ≈ $151.14 Million |
0.344x | -36.01% |
| 2005-09-30 | Dkr2.51 Billion ≈ $393.33 Million |
Dkr1.35 Billion ≈ $211.69 Million |
0.538x | +51.45% |
| 2004-09-30 | Dkr2.37 Billion ≈ $370.25 Million |
Dkr840.90 Million ≈ $131.57 Million |
0.355x | -21.60% |
| 2003-09-30 | Dkr2.01 Billion ≈ $314.48 Million |
Dkr911.00 Million ≈ $142.53 Million |
0.453x | -22.11% |
| 2002-09-30 | Dkr1.57 Billion ≈ $245.48 Million |
Dkr913.00 Million ≈ $142.85 Million |
0.582x | -- |
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, wh… Read more